[go: up one dir, main page]

LT3125894T - Živ atvirkštinės transkriptazės inhibitorių provaistai - Google Patents

Živ atvirkštinės transkriptazės inhibitorių provaistai

Info

Publication number
LT3125894T
LT3125894T LTEP15774282.6T LT15774282T LT3125894T LT 3125894 T LT3125894 T LT 3125894T LT 15774282 T LT15774282 T LT 15774282T LT 3125894 T LT3125894 T LT 3125894T
Authority
LT
Lithuania
Prior art keywords
prodrugs
reverse transcriptase
transcriptase inhibitors
hiv reverse
hiv
Prior art date
Application number
LTEP15774282.6T
Other languages
English (en)
Inventor
Christopher Burgey
Jeffrey FRITZEN
Jaume Balsells
Mehul Patel
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of LT3125894T publication Critical patent/LT3125894T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEP15774282.6T 2014-04-01 2015-03-27 Živ atvirkštinės transkriptazės inhibitorių provaistai LT3125894T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973689P 2014-04-01 2014-04-01
PCT/US2015/022868 WO2015153304A1 (en) 2014-04-01 2015-03-27 Prodrugs of hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
LT3125894T true LT3125894T (lt) 2020-12-10

Family

ID=54241131

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15774282.6T LT3125894T (lt) 2014-04-01 2015-03-27 Živ atvirkštinės transkriptazės inhibitorių provaistai

Country Status (21)

Country Link
US (1) US10004740B2 (lt)
EP (2) EP3785714A1 (lt)
JP (1) JP6342011B2 (lt)
KR (1) KR102440843B1 (lt)
CN (1) CN106456639B (lt)
AU (1) AU2015241247B2 (lt)
BR (1) BR112016022722B8 (lt)
CA (1) CA2944187C (lt)
CY (1) CY1123582T1 (lt)
DK (1) DK3125894T3 (lt)
ES (1) ES2828951T3 (lt)
HR (1) HRP20201780T1 (lt)
HU (1) HUE051848T2 (lt)
LT (1) LT3125894T (lt)
MX (1) MX2016012915A (lt)
PL (1) PL3125894T3 (lt)
PT (1) PT3125894T (lt)
RS (1) RS61016B1 (lt)
RU (1) RU2693622C2 (lt)
SI (1) SI3125894T1 (lt)
WO (1) WO2015153304A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
LT3125894T (lt) 2014-04-01 2020-12-10 Merck Sharp & Dohme Corp. Živ atvirkštinės transkriptazės inhibitorių provaistai
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维(上海)医药科技发展有限公司 一种嘧啶衍生物的制备方法
WO2019124548A1 (ja) 2017-12-22 2019-06-27 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除剤
MA54549A (fr) 2018-12-18 2022-03-30 Merck Sharp & Dohme Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih
EP3928834A4 (en) 2019-02-20 2022-10-12 Sumitomo Chemical Company Limited Ether compound and harmful arthropod-controlling composition containing same
AU2020279954B2 (en) * 2019-05-22 2025-11-13 Merck Sharp & Dohme Llc Pyridinone derivatives as selective cytotoxic agents against HIV infected cells
WO2021011513A1 (en) 2019-07-16 2021-01-21 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
WO2022208370A1 (en) 2021-03-31 2022-10-06 Pi Industries Ltd. Fused heterocyclic compounds and their use as pest control agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
NZ541902A (en) 2003-02-07 2008-12-24 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US7288942B2 (en) * 2003-10-02 2007-10-30 Naoyuki Sato Plasma potential measuring method and apparatus, and plasma potential measuring probe
US20050282839A1 (en) 2004-01-12 2005-12-22 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
WO2005090317A1 (en) * 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
AU2005235692B2 (en) 2004-04-23 2011-11-10 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
CA2592092A1 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ATE425138T1 (de) 2005-10-19 2009-03-15 Hoffmann La Roche N-phenyl-phenylacetamid-nichtnukleosidinhibitor n reverser transkriptase
CA2625047A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
MX2009005449A (es) 2006-11-24 2009-06-02 Takeda Pharmaceutical Compuesto heteromonociclico y uso del mismo.
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
US8404253B2 (en) 2006-12-28 2013-03-26 Newport Laboratories, Inc. Modified live (JMSO strain) Haemophilus parasuis vaccine
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
MX2010005483A (es) 2007-11-20 2010-06-11 Merck Sharp & Dohme Inhibidores de transcriptasa inversa no nucleosidos.
JP5564435B2 (ja) * 2008-01-08 2014-07-30 メルク・シャープ・アンド・ドーム・コーポレーション N−置換ヒドロキシピリミジノンカルボキサミドの製造方法
ME02181B (me) * 2010-03-30 2015-10-20 Merck Canada Inc Ne-nukleozidni inhibitori reverzne transkriptaze
US20130040914A1 (en) * 2010-04-08 2013-02-14 Samson M. Jolly Prodrugs of an hiv reverse transcriptase inhibitor
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
LT3125894T (lt) 2014-04-01 2020-12-10 Merck Sharp & Dohme Corp. Živ atvirkštinės transkriptazės inhibitorių provaistai

Also Published As

Publication number Publication date
CN106456639A (zh) 2017-02-22
AU2015241247B2 (en) 2017-09-14
PL3125894T3 (pl) 2021-02-08
BR112016022722B8 (pt) 2023-11-21
CA2944187A1 (en) 2015-10-08
ES2828951T3 (es) 2021-05-28
JP2017512802A (ja) 2017-05-25
RU2693622C2 (ru) 2019-07-03
WO2015153304A1 (en) 2015-10-08
EP3125894A1 (en) 2017-02-08
CN106456639B (zh) 2019-05-10
JP6342011B2 (ja) 2018-06-13
RS61016B1 (sr) 2020-12-31
EP3125894A4 (en) 2017-12-13
CY1123582T1 (el) 2022-03-24
MX2016012915A (es) 2016-12-07
HUE051848T2 (hu) 2021-03-29
RU2016142611A (ru) 2018-05-03
US20170173015A1 (en) 2017-06-22
KR102440843B1 (ko) 2022-09-29
BR112016022722B1 (pt) 2023-03-07
EP3785714A1 (en) 2021-03-03
SI3125894T1 (sl) 2020-12-31
EP3125894B1 (en) 2020-09-09
BR112016022722A2 (pt) 2017-10-31
DK3125894T3 (da) 2020-11-16
PT3125894T (pt) 2020-11-05
RU2016142611A3 (lt) 2018-12-26
US10004740B2 (en) 2018-06-26
CA2944187C (en) 2018-06-19
HRP20201780T1 (hr) 2021-06-25
KR20160133000A (ko) 2016-11-21
AU2015241247A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
AP2016009482A0 (en) 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
ZA201604272B (en) Inhibitors of glutaminase
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
LT3125894T (lt) Živ atvirkštinės transkriptazės inhibitorių provaistai
IL256427A (en) ido inhibitors
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
DK3204352T3 (da) Hæmmere af lysin-gingipain
LT3226888T (lt) Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
GB201402169D0 (en) Viral inhibitors
GB201407822D0 (en) Use of a composition
GB201401005D0 (en) Inhibitor
HUP1500506A2 (en) Salts of palbociclib
GB201417348D0 (en) Prodrugs of lxazomib
GB201417347D0 (en) Prodrugs of delanzomib
TH1501005447A (th) สารยับยั้ง ido
GB201417192D0 (en) Deposition of graphene
GB201418154D0 (en) Inhibitors
GB201417343D0 (en) Prodrugs of bortezomib
GB201414132D0 (en) Prodrugs of bortezomib